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Introduction
Dermatoporosis is a novel term proposed to describe the
chronic cutaneous insufficiency/fragility syndrome (1-3). As in
osteoporosis where the bone mass is progressively decreased,
the dermatoporosis is caused by the progressive decrease of the
main structural elements of the skin (Figure 1). Dermatoporosis
is considered to be the functional face of skin aging beyond
cosmetics and appearance. As of 40-60 years-old, the trivial
signs of skin aging such as wrinkles and appearance changes
occur. At 70-80 years-old, morphological markers of
dermatoporosis start to appear. As from 80 years-old,
functional expression of skin fragility with the complications of
dermatoporosis begins. This syndrome needs to be better
studied in order to find preventive solutions. With increasing
numbers of elderly patients over 80 years-old, we start talking
about the epidemics of dermatoporosis. Chronic systemic or
topical steroid therapy and chronic exposure to ultraviolet
irradiation seem to be the major causes of dermatoporosis (2). 
Morphological markers of dermatoporosis
Skin atrophy
Skin atrophy is seen clinically as extreme thinning of the
skin with the appearance of wrinkles (Figure 1D). Echographic
analysis of the skin shows a significant decrease of the skin
thickness (epidermis and dermis) (0.5-0.8 mm) when compared
to that of the normal skin (1.2-1.5 mm).
Senile purpura
Senile purpura (or purpura of Bateman) is a superficial non-
inflammatory hemorrhagic lesion histologically characterized
by extravasation of erythrocytes in an atrophic dermis due to
vascular fragility (Figure 1D).
Figure 1
As in osteoporosis where the bone mass is progressively
decreased (A, C), the dermatoporosis is caused by the
progressive decrease of the main structural elements of the skin
(B, D)
Pseudoscar
Pseudoscar is a superficial scar due to the spontaneous
laceration of the skin secondary to minor trauma (Figure 1D).
Histologically these lesions correspond to a hypocellular
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sclerotic and fibrotic zone covered by an atrophic epidermis.
Prevalance of dermatoporosis
According to a French study conducted on 202 subjects
ranging between 60 and 80 years, the prevalence of
dermatoporosis is as high as 32%. The frequency of
dermatoporosis is about 22% in females and 38% in males (4).
Topography of dermatoporosis 
The zones of predilection of dermatoporosis are the
following (according to frequency): posterior side of forearms,
pretibial area, dorsum of hands, presternal area and scalp
(Figure 2). This suggests different internal and external
etiological factors.
Clinical stages of dermatoporosis
Four stages of dermatoporosis have been proposed (2):
Stage I: In this stage we find the abovementioned
morphological markers of dermatoporosis i.e. skin atrophy,
senile purpura and pseudocicatrices. This is the most common
stage of dermatoporosis.    
Stage IIa: Localized and small superficial lacerations (<3
cm) due to skin fragility.
Stage IIb: Larger lacerations (>3 cm).
Stage IIIa: Superficial hematomas.
Stage IIIb: Deep dissecting hematomas without skin
necrosis.
Stage IV: Large areas of skin necrosis with potential lethal
complications. 
Figure 2
The zones of predilection of dermatoporosis are posterior side
of forearms (A), dorsum of hands (B), presternal area (C) and
scalp (D)
Deep dissecting hematoma (DDH)
DDH is an emerging severe complication of dermatoporosis
(5). Following a minor traumatic event, laceration of deep skin
vessels exposed to skin surface due to the extreme thinning of
epidermis and dermis and to the loss of viscoelastic capacity of
the dermatoporotic skin seems to be the pathogenetic
mechanism. Prompt diagnosis by clinical evaluation and
imaging procedures and early drainage of the hematoma by
surgical intervention are critical to save the life of the patient.
Mechanisms of skin fragility in dermatoporosis
Hyalurosome dysfunction
We have recently proposed a membrane organelle,
hyalurosome, composed of molecules involved in hyaluronate
(HA) metabolism and cell signaling in the keratinocytes, such
as CD44, heparin-binding epidermal growth factor (HB-EGF)
and HB-EGF receptor erbB1, which is functionally defective in
dermatoporosis (6) (Figure 3). Hyalurosome mainly functions
as a HA factory. The production and the degradation of HA are
realized by hyaluronate synthase (HAS) and hyaluronidase
(Hyal) enzymes, respectively. There are three mammalian
HASs (HAS1, HAS2 and HAS3) which synthesize HA of
different sizes at the cell membrane and release it to the
extracellular area where it binds to proteoglycans such as
CD44. CD44 is a transmembrane glycoprotein and the major
cell surface receptor of HA (7). There are several isoforms of
CD44 resulting from alternative splicing and post-translational
modifications. The standard form and the variant forms are
designated as CD44s and CD44v, respectively. A particular
isoform of CD44, CD44v3, is expressed by keratinocytes. We
have recently shown that HAS3 is co-localized with CD44v3
and HA in human epidermis, suggesting that hyalurosome is
found on the keratinocyte membrane (8). In fact, HAS3
transfection of cultured epithelial cells induces filopodia
formation with consequential HA accumulation around
filopodia (9). This observation implies that hyalurosome is
located on the filopodia. Filopodia are thin, actin-rich plasma
membrane protrusions and among the distinct leading edge
structures implicated in cell motility (10, 11). We have recently
demonstrated that CD44v3, HA and actin were co-localized in
the filopodia of cultured keratinocytes (manuscript in
preparation). Suppression of keratinocyte CD44 results in skin
atrophy, which is very similar to dermatoporosis, in mouse
(12). We have shown that CD44 and HA expressions are
decreased in human dermatoporotic skin (2).  We have also
shown that the expression of hyalurosome molecules is
diminished in dermatoporosis patients (manuscript in
preparation). We also observed a decrease in HA production, in
the expression of hyalurosome molecules and in filopodia
formation in cultured keratinocytes treated with corticosteroids
(manuscript in preparation). 
Ultraviolet (UV) irradiation
We have previously shown that UVA and UVB irradiation
decrease the expression of CD44 and HA in mouse skin,
suggesting the deleterious effect of UV on hyalurosome
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Figure 3
Schematic representation of hyalurosome composed of
CD44 platform molecules (CD44v3, HB-EGF, matrix
metalloproteinase-7 (MMP-7) and erbB1), HAS and Hyal. The
activity of hyalurosome is triggered by an exogenous or
endogenous signal which, through a starter molecule, induces
the CD44 platform molecules and HAS. The synthesis of HA
molecules is controlled by Hyal (A). Induction of CD44
platform molecules localized at the cell membrane results in
keratinocyte stimulation and HA synthesis (B)
Topical corticosteroids
We have recently shown that topical steroids induce a severe
skin atrophy and decrease the expression of CD44, CD44v3
and pro-HB-EGF as well as the epidermal and dermal HA
content in mouse skin in only 5 days (14).   
Correction of hyalurosome deficiency in dermatoporosis
HA is a high molecular weight polysaccharide (106 Da)
which is the major component of the extracellular matrix
(ECM) of the skin. HA has structural and mechanical functions
such as viscoelasticity, filling and hydration (15). HA
fragments (HAF) (>8x102 Da - <106 Da) are generated in case
of stress and injury and have signaling functions playing a role
in cell renewal and angiogenesis (16). We hypothesized that
activation of hyalurosome by HAF might be an option to
reverse skin atrophy in dermatoporosis.
Effect of HAF of defined size on keratinocytes
In order to understand the effect of HAF on keratinocytes,
we generated HAF of small (HAFs), intermediate (HAFi) and
large size (HAFl). HAFi, but not HAFs or HAFl, induced in
vitro mouse keratinocyte proliferation (17). HAFi increased
HA production in vitro in human keratinocytes. HAFi, but not
HAFs or HAFl, also increased the number and size of filopodia
in cultured keratinocytes (manuscript in preparation).
Effect of HAFi on mouse skin
HAFi result in a CD44-dependent epidermal hyperplasia and
increase the quantity of epidermal and dermal HA in mouse
skin. HAFi also increase the protein expression of CD44v3,
pro- and active HB-EGF in mouse skin (17). Topical HAFi
prevent the skin atrophy induced by topical corticosteroids in
mice without interfering with their anti-inflammatory effect.
Topical HAFi also restore diminished expression of CD44,
CD44v3 and pro-HB-EGF, and augment the epidermal and
dermal HA content in mouse skin treated with topical
corticosteroids (14).  
Effect of HAFi on the skin of dermatoporosis patients
Topical treatment with HAFi 1% of atrophic forearm skin of
dermatoporosis patients for 1 month resulted in a significant
clinical improvement with decrease of purpuric lesions and
atrophic aspect of the skin (17). Histologically, epidermal
atrophy was corrected and the dermal cellularity was increased.
Echographic analysis of the skin showed that in elderly patients
(74-86 years-old) the cutaneous thickness was significantly
increased with HAFi treatment. In patients aged between 55
and 65 years where the skin atrophy was less pronounced, the
effect of HAFi was minimal. In young controls (29-32 years-
old) with no skin atrophy, there was no effect of HAFi. HA-
Binding Protein (HABP) staining of dermatoporotic skin
revealed a significant increase of HA content after HAFi
treatment (manuscript in preparation).  HAFi increased also the
collagen, elastin and vascular content in the dermis of
dermatoporotic skin after 1 month of treatment (17). Topical
HAFi induced the expression of hyalurosome molecules in
dermatoporotic skin (manuscript in preparation).  
Synergistic effect of HAFi and retinoids
Topical retinoids are known to cause an epidermal
hyperplasia by inducing HB-EGF (18). We have previously
shown that topical retinaldehyde (RAL) increases the
expression of CD44v3 and that the hyperplasie-inducing effect
of RAL was abolished in CD44KO mice (19). RAL augments
the epidermal and dermal content of HA by inducing the HASs
(20). Topical RAL also prevents UV-induced decrease of CD44
and HA expression in mouse skin (13). Treatment of primary
mouse keratinocyte cultures with RAL resulted in the most
significant increase in keratinocyte proliferation when
compared with other retinoids, retinoic acid, retinol or retinoyl
palmitate. RAL and HAFi showed a more significant increase
in keratinocyte proliferation than RAL or HAFi alone (6). We
observed a synergy between RAL and HAFi in HA production
and pro-HB-EGF expression in mouse skin and in the
correction of skin atrophy in dermatoporosis patients (Figure 4)
(6). RAL and HAFi also increase the HA and collagen content
and decrease the number of senile purpura in dermatoporotic
skin (manuscript in preparation).  
JNHA: NUTRITION
The Journal of Nutrition, Health & Aging©
Volume 16, Number 4, 2012
287
288
The Journal of Nutrition, Health & Aging©
Volume 16, Number 4, 2012
NEW THERAPEUTIC TARGETS IN DERMATOPOROSIS
Figure 4
Clinical aspect of dermatoporotic forearm skin before (A) and 1
month after topical treatment with RAL and HAFi (B). Note the
disappearance of senile purpura and improvement of atrophy.
Echographic analysis performed using a skin ultrasound system
(Episcan®; Longport Inc., Glen Mills, PA, USA) shows the
correction of skin atrophy (average of 3 measurements between
the top level of epidermis and dermal-subcutaneous fat
junction). Average cutaneous thickness before treatment (0.63
mm; C) and after 1 month of topical treatment (1.14 mm; D)
Conclusion
Hyalurosome seems to be a molecular target in
dermatoporosis. We think that the dysfunction of hyalurosome
reflected by decreased HA synthesis and filopodia formation
plays a central role in skin atrophy in dermatoporosis. We have
identified HAFi as an anti-atrophic factor which acts on
hyalurosome to correct its dysfunction by stimulating HASs,
CD44, HB-EGF and filopodia alone or in synergy with RAL.
Further research is needed to shed more light on the
understanding of other molecular pathways implicated in
dermatoporosis and to develop therapeutic strategies targeting
hyalurosome.
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